newsfilter
← Latest News
Business Wire·

PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights

– FREEDOM2-DM1 5 mg/kg cohort data expected in Q1 2026 – – Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected in 2H 2026 – – FREEDOM2 trial open in South Korea,